Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/9/2020
SIETES contiene 93096 citas

 1 a 20 de 145 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699-700. [Ref.ID 102019]
2.Tiene citas relacionadas Cita con resumen
Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699. [Ref.ID 102018]
3. Cita con resumen
Wang Y, Zhao X, Lin J, Johnston C, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, for the CHANCE Investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016;316:70-8. [Ref.ID 100516]
4.Tiene citas relacionadas Cita con resumen
Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin. Even the score does not add up . JAMA Intern Med 2016;176:439-42. [Ref.ID 100071]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med 2016;176:febrero. [Ref.ID 99958]
6. Cita con resumen
Young K. FDA advisers back approval of first drug for female sexual dysfunction. Journal Watch 2015:1. [Ref.ID 99241]
7. Cita con resumen
Anónimo. Which PPI?. Med Lett Drugs Ther 2015;57:8-9. [Ref.ID 99216]
8. Cita con resumen
Anónimo. Vortioxetine (Brintellix) for depression. Med Lett Drugs Ther 2013;55:93. [Ref.ID 96686]
9. Cita con resumen
Anónimo. Dabrafenib (Tafinlar) and trametinib (Mekinist) for metastatic melanoma. Med Lett Drugs Ther 2013;55:62-3. [Ref.ID 95948]
11. Cita con resumen
Anónimo. Two new drugs for weight loss. Med Lett Drugs Ther 2012;43:69-71. [Ref.ID 93703]
12. Cita con resumen
Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012;307:2495-6. [Ref.ID 93316]
13. Cita con resumen
Uotani T, Sugimoto M, Nishino M, Kodaira C, Yamade M, Sahara S, Yamada T, Osawa S, Sugimoto K, Tanaka T, Umemura K, Watanabe H, Miyajima H, Furuta T. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. Clin Gastroenterol Hepatol 2012;10:879-85. [Ref.ID 92939]
14.Tiene citas relacionadas Cita con resumen
Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis J-F, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DYF. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012;370:1705-11. [Ref.ID 92880]
15.Tiene citas relacionadas
Beitelshees AL. Personalised antiplatelet treatment: a RAPIDly moving target. Lancet 2012;370:1680-2. [Ref.ID 92871]
16. Cita con resumen
Mega JL, Hochholzer W, Frelinger III AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221-8. [Ref.ID 91846]
17.Enlace a cita original
Ma TKW, Lam Y-Y, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. Eur J Clin Pharmacol 2011;72:697-706. [Ref.ID 91569]
18.Tiene citas relacionadas Cita con resumen
Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis . BMJ 2011;343:353. [Ref.ID 91193]
19.Tiene citas relacionadas
Holmes MV, Casas JP, Hingorani AD. Putting genomics into practice. BMJ 2011;343:327-8. [Ref.ID 91192]
20.Tiene citas relacionadas Cita con resumen
Wallentin L, for the PLATO genetics substudy co-authors. Genetic substudy of the PLATO trial. Authors' reply. Lancet 2011;377:637-8. [Ref.ID 90239]
Seleccionar todas
 1 a 20 de 145 siguiente >>